CN1634407A - Chinese traditional medicine preparation for treating cholecystitis - Google Patents
Chinese traditional medicine preparation for treating cholecystitis Download PDFInfo
- Publication number
- CN1634407A CN1634407A CN 200410086352 CN200410086352A CN1634407A CN 1634407 A CN1634407 A CN 1634407A CN 200410086352 CN200410086352 CN 200410086352 CN 200410086352 A CN200410086352 A CN 200410086352A CN 1634407 A CN1634407 A CN 1634407A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- preparation
- parts
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese traditional medicine preparation for treating cholecystitis, which is prepared from nine Chinese medicinal herbs including oriental wormwood, baikal skullcap root, Bupleurum root, curcuma aromatica, corydalis tuber, mentha, cardamorn, notoginseng, capsule of weeping forsythia.
Description
Technical field:
The present invention relates to a kind of Chinese medicine preparation for the treatment of cholecystitis, particularly relate to the preparation that Herba Artemisiae Scopariae, Radix Scutellariae, Radix Bupleuri, Radix Curcumae, Rhizoma Corydalis, Herba Menthae, Fructus Amomi Rotundus, Radix Notoginseng, Fructus Forsythiae nine flavor Chinese medicines are made.
Background technology:
Chronic cholecystitis is clinical common, multiple disease.Though symptom is not serious clinically, stubbornness does not heal, and often because of the rich back sx of taking food, causes acute attack.Along with people living condition's improvement, the food component mismatch, the sickness rate of primary disease day by day increases.(the new traditional Chinese medical science 1996,5:19-21).The reported literature sickness rate is about 10%.The most concurrent cholelithiasis of chronic cholecystitis, doctor trained in Western medicine is at present mainly with operative treatment, but the postoperative recurrence rate can reach more than 40%.Chinese medicine is that method treatment has report more with lithodialysis, calculus in recent years, and total effective rate does not wait at 26-90%, and free rate is no more than 30%, still lacks superior Chinese-western medicine preparation of curative effect and Study on Correlative Mechanisms aspect the clinical symptoms improving.(Journal of Traditional Chinese Medicine 1996,37 (12), 725-727).Therefore, a medicine for the treatment of chronic cholecystitis safely and effectively, the chronic cholecystitis patient is needed just.
China chronic cholecystitis patient surpasses 100,000,000, and this type of medicine has vast market prospect, as DANTONG, and this strain Germany import medicine, China need expend more than one hundred million foreign exchanges every year and buy this medicine to satisfy the demand of domestic market.Yet, Western medicine not only costs an arm and a leg, curative effect be not yet introduce said effective like that, and should disease need take medicine for a long time, the potential toxic and side effects of Western medicine is then made us load and is disturbed, therefore, similar Chinese patent medicine just becomes clinical ideal medicine, cause people's great interest, in order to satisfy the demand of medical market better, remove the common people's misery, improve this class disease patient's quality of life, develop determined curative effect, the medicine that is used for chronic cholecystitis has become one of urgent key subjects that solve of the world of medicine.
Chronic cholecystitis belongs to categories such as the traditional Chinese medical science " hypochondriac pain ", " gallbladder-distention ", and diseased region is involved in liver at gallbladder, bile excretion is logical to fall function needs the irritability bar to reach especially, if the irritability catharsis is not normal, then bile is stopped up and stagnated, strongly fragrant and heat-transformation, the retardance mechanism of qi, so hot and suffocating be the pathologic basis of chronic cholecystitis.With the passing of time dampness-heat in the liver and gallbladder smoulders, and channels is not smooth, cholestasis, and blood stagnation becomes the stasis of blood.Modern pathological study is thought, the chronic cholecystitis thickening of capsule wall of gallbladder, and with the surrounding tissue adhesion, or scar tissue fibrosis, contraction are arranged, blister cavities is narrowed down, mucosa injury, wall has lymphocytic infiltration, is because gallbladder wall blood follows due to the long-term obstacle.This is the essence of the stasis of blood.So in treatment, answer clearing heat and expelling damp, depressed liver-energy dispersing and function of gallbladder promoting, promoting blood circulation and stopping pain.
The present invention is prescription in view of the above.Herba Artemisiae Scopariae clearing away heat-damp and promoting diuresis in the side, promoting the function of the gallbladder to alleviate jaundice, kind especially liver heat removing gallbladder is damp and hot, is monarch drug; The Radix Scutellariae dispelling the damp pathogen with drugs of bitter in taste and cold in nature is damp and hot with principal drug assistance digestion, and Radix Bupleuri dispersing the stagnated live-QI to relieve the stagnation of QI, reducing fever by reconciliation, are let out the blood removing blood stasis with potent drugs at the Radix Curcumae promoting QI circulation for relieving depression, Radix Bupleuri is joined the effect that Radix Scutellariae has reducing fever by reconciliation, and 5 Radix Curcumaes have the merit of promoting QI circulation for relieving depression, and three medicines all have good choleretic effect, the heat clearing away of energy principal drug assistance function of gallbladder promoting is ministerial drug in the side altogether; The pain relieving of Rhizoma Corydalis promoting flow of QI and blood, the Herba Menthae dispersing the stagnated live-QI to relieve the stagnation of QI, Fructus Amomi Rotundus removing dampness by means of aromatics, the alleviating distention in middle-JIAO that helps digestion, Typhonium flagelliforme (Lodd.) Blume blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, more than four flavors be altogether adjuvant drug in the side; Fructus Forsythiae heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, and can draw the through sick institute of all medicines are messenger drug in the side, and all medicines mutually 5 are played the effect of clearing heat and expelling damp, depressed liver-energy dispersing and function of gallbladder promoting, promoting blood circulation and stopping pain altogether.
Chinese medicines of more existing treatment cholecystitis belong to a bit cures the symptoms, not the disease, and some uses expensive composition, and some interrupts use because uncertain therapeutic efficacy is cut in application process.
The invention provides a kind of determined curative effect, safe ready, little, the cheap pure traditional Chinese compound medicine of side effect.
Summary of the invention:
The invention provides a kind of pharmaceutical preparation of making by nine flavor Chinese medicines such as Herba Artemisiae Scopariae, Radix Scutellariae, Radix Bupleuri, Radix Curcumae, Rhizoma Corydalis, Herba Menthae, Fructus Amomi Rotundus, Radix Notoginseng, Fructus Forsythiae.
Preparation of the present invention is to be processed into by the prescription process of following proportioning.
Herba Artemisiae Scopariae 475-1900 part Radix Scutellariae 427-1710 part Radix Bupleuri 427-1710 part Radix Curcumae 427-1710 part
Radix Notoginseng 95-380 part Fructus Forsythiae 237-950 part Fructus Amomi Rotundus 237-950 part Rhizoma Corydalis 237-950 part
Herba Menthae 237-950 part
Preferred prescription is:
Herba Artemisiae Scopariae 712-1266 part Radix Scutellariae 641-1140 part Radix Bupleuri 641-1140 part Radix Curcumae 641-1140 part
Radix Notoginseng 142-253 part Fructus Forsythiae 356-633 part Fructus Amomi Rotundus 356-633 part Rhizoma Corydalis 356-633 part
Herba Menthae 356-633 part
Most preferred prescription is:
855 parts of 855 portions of Radix Curcumaes of 855 parts of Radix Bupleuri of 950 parts of Radix Scutellariaes of Herba Artemisiae Scopariae
475 parts of 475 parts of Rhizoma Corydalis of 475 parts of Fructus Amomi Rotunduss of 190 parts of Fructus Forsythiaes of Radix Notoginseng
475 parts of Herba Menthaes
In more than forming, described part is weight portion, weight is calculated with crude drug, if it is that unit can be made into 1000 units of pharmaceutical preparation that this prescription is formed with gram (g), described 1000 units refer to, the final drug preparation unit of making, as make 1000 of capsule preparations, 1000 in tablet, granule 1000g, pellet 1000g, oral liquid 1000ml etc. for granule or pellet, can dress up in the pouch of different capabilities, dress up 125 bags, 200 bags, 250 bags or 500 bags etc. as 1000g granule or pellet, every bag can be used as 1 time or 2 taking doses.
More than form, can be made into the preparation of 50-1000 taking dose, as tablet, make 1000, each taking dose can be the 1-20 sheet, can take 50-1000 time altogether.
More than form to be by weight as proportioning, when producing, can increase or reduce according to corresponding proportion, as large-scale production can be unit with the kilogram, or be unit with the ton, small-scale production can be a unit with gram or milligram also, weight can increase or reduce, but the constant rate of the raw medicinal herbs weight proportion between each composition.
The ratio of above weight proportion obtains through science screening, for especial patient, and as serious symptom or light disease, fat or modest patient, the proportioning of the amount of can corresponding adjustment forming increases or reduces being no more than 100%, and drug effect is constant.
Raw material of Chinese medicine, especially ministerial drug and adjuvant drug in more than forming also can be replaced by the suitable Chinese medicine with identical property of medicine, and its drug effect of the Chinese medicine preparation after the replacement is constant.
Chinese medicine preparation of the present invention is to process through extraction or other modes by the raw material of Chinese medicine that above-mentioned prescription is formed, and makes pharmaceutically active substance, subsequently, with this active substance is raw material, adds the medicine acceptable carrier when needing, and makes according to the routine techniques of galenic pharmacy.Described active substance can obtain by extracting raw material of Chinese medicine respectively, also can obtain by the co-extracted raw material of Chinese medicine, also can obtain by other modes, as: by pulverize, squeeze, calcine, grind, sieve, percolation, extraction, water are carried, alcohol extraction, ester is carried, methods such as ketone is carried, chromatography obtain, obtained by above method active substance can be the materials of extractum form, can be that dry extract also can be a fluid extract, make different concentration according to the different needs decision of preparation.
Pharmaceutically active substance in the pharmaceutical preparation of the present invention, its shared percentage by weight in preparation can be 0.1-99.9%, all the other are the medicine acceptable carrier.Pharmaceutical preparation of the present invention exists with unit dosage form, and described unit dosage form is meant the unit of preparation, as every of tablet, and capsular every capsules, every bottle of oral liquid, every of micropill etc.
Pharmaceutical preparation of the present invention can be any pharmaceutically useful dosage form, these dosage forms comprise: pellet, tablet, capsule, oral liquid, syrup, granule, pill, powder, unguentum, sublimed preparation, injection, suppository, cream, spray, drop pill, patch, slow releasing preparation, controlled release preparation.
Pharmaceutical preparation of the present invention, the preparation of its oral administration can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent.
The filler that is suitable for comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Can fill by mixing, the method that tabletting etc. are commonly used prepares solid oral composition.Mix repeatedly active substance is distributed in those compositionss of a large amount of filleies of whole use.
The form of oral liquid for example can be aqueous or oily suspensions, solution, Emulsion, syrup or elixir, perhaps can be a kind of available water before use or other suitable composite dry products of carrier.This liquid preparation can contain conventional additive, such as suspending agent, for example sorbitol, syrup, methylcellulose, gelatin, hydroxyethyl-cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenation edible fat, emulsifying agent, for example lecithin, anhydro sorbitol monooleate or arabic gum; Non-aqueous carrier (they can comprise edible oil), for example almond oil, fractionated coconut oil, such as oily ester, propylene glycol or the ethanol of the ester of glycerol; Antiseptic, for example para hydroxybenzene methyl ester or propyl p-hydroxybenzoate or sorbic acid, and if desired, can contain conventional flavouring agent or coloring agent.
For injection, the liquid unit dosage forms of preparation contains active substance of the present invention and sterile carrier.According to carrier and concentration, this chemical compound can be suspended or dissolving.The preparation of solution is normally by being dissolved in active substance in a kind of carrier filter-sterilized before it is packed into a kind of suitable bottle or ampoule, sealing then.For example a kind of local anesthetic of adjuvant, antiseptic and buffer agent also can be dissolved in this carrier.In order to improve its stability, can be after the bottle of packing into that this compositions is freezing, and under vacuum, water is removed.
Pharmaceutical preparation of the present invention, when being prepared into medicament, optionally add suitable medicine acceptable carrier, described medicine acceptable carrier is selected from: mannitol, sorbitol, sodium pyrosulfite, sodium sulfite, sodium thiosulfate, cysteine hydrochloride, TGA, methionine, vitamin C, the EDTA disodium, EDTA calcium sodium, the alkali-metal carbonate of monovalence, acetate, phosphate or its aqueous solution, hydrochloric acid, acetic acid, sulphuric acid, phosphoric acid, aminoacid, sodium chloride, potassium chloride, sodium lactate, xylitol, maltose, glucose, fructose, dextran, glycine, starch, sucrose, lactose, mannitol, silicon derivative, cellulose and derivant thereof, alginate, gelatin, polyvinylpyrrolidone, glycerol, soil temperature 80, agar, calcium carbonate, calcium bicarbonate, surfactant, Polyethylene Glycol, cyclodextrin, beta-schardinger dextrin-, the phospholipid material, Kaolin, Pulvis Talci, calcium stearate, magnesium stearate etc.
Preparation of the present invention is determined usage and dosage according to patient's situation in use, but obeys 1-4 time every day, each 1-20 dosage unit, as: 1-20 bottle or sheet or gram.
Pharmaceutical preparation of the present invention can prepare by the following method:
Seal after [method for making] Radix Notoginseng beats fine powder, use
60The sterilization of CO-radiation gamma is standby.Rhizoma Corydalis grinds the back with 80% ethanol extraction secondary, and 6 times of amounts were extracted 1.5 hours for the first time, adds 5 times of amounts the 2nd time to extract 1 hour, merges the secondary alcohol extract, and is standby behind the recovery ethanol.Six medicaments such as Herba Artemisiae Scopariae add 10 times of water gagings and soak into post-heating backflow 1 hour, regather the distillate of 6 times of amounts; Redistillation is collected volatile oil, and it is added beta-schardinger dextrin-polishing enclose, and dry back is standby.Mix above-mentioned medicinal residues, add 6 times of water gagings after adding Radix Scutellariae, boiled 2.0 hours, leach medicinal residues, adding 5 times of water gagings again boiled 1.5 hours, merging filtrate is incorporated the alcohol extract of Rhizoma Corydalis into when being evaporated to relative density and being 1.35～1.38 (60 ℃ of heat are surveyed), in 60 ℃ ,-0.08Mpa under vacuum drying, the gained extract powder, Radix Notoginseng fine powder, Benexate Hydrochloride are made the pharmaceutical dosage form that is fit to take together as pharmaceutically active substance with this pharmaceutically active substance with the galenic pharmacy routine techniques.
The particularly preferred pharmaceutical dosage form of the present invention is the micropill dosage form, and this dosage form can be by making the general ball of binding agent with the pharmaceutically active substance of above preparation with 15% sucrose water, and control ball footpath promptly gets the 1000g micropill after the drying about 2mm.Pharmaceutical preparation of the present invention has clearing away heat-damp and promoting diuresis, depressed liver-energy dispersing and function of gallbladder promoting, promoting blood circulation and stopping pain effect.Be used for damp-heat accumulation and hold stasis type chronic cholecystitis and chronic cholecystitis under the arm.
Following data declaration beneficial effect of the present invention by experiment.
Pharmacodynamics test:
Adopt the micropill (being called the clear micropill of function of gallbladder promoting) of the preparation method preparation of the embodiment of the invention 1 to carry out following experiment at this:
1, test material
1,1 medicine
The clear micropill of function of gallbladder promoting, carrying forward medical sci-tech development company by Changsha provides, and lot number 970105 faces the time spent to be mixed with the concentration of needs with distilled water.Test set basic, normal, high dosage and be equivalent to 0.5,1.0,2.0 times of clinical equivalent dosage respectively approximately.
XIAOYAN LIDAN PIAN, Guangxi Ji people pharmaceutical factory, lot number 971023 faces the time spent to be mixed with needed concentration with distilled water and to test set dosage and be equivalent to 2 times of clinical equivalent dosage approximately.
Trepibutone tables is produced by strain state, the Hunan Hunan pharmaceutical factory of traditional Chinese medicine, and lot number 970803 faces the time spent to be mixed with needed concentration with distilled water.
Aspirin is produced by Hunan pharmaceutical factory, lot number 970508, and facing the time spent has distilled water to be mixed with needed concentration.
1,2 animals
The NIH white mice, 18---22g, ♂, ♀ have concurrently, and the moving word of quality certification lake doctor 20-001 number is provided by Hu'nan Inst. of Plarmaceutical Industry.The SD rat, body weight 180----220g, ♂, body weight 294.5 ± 77.1g, ♂ is provided by Hu'nan Inst. of Plarmaceutical Industry, the quality certification number: the moving word of Hunan doctor 20----002 number.
1.3 instrument and main agents
Dimethylbenzene: chemical reagent factory in the Hengyang City four, lot number 950704.Formaldehyde: Changsha prolongs air slaking chemical reagent work, lot number 960211.Acetic acid: Hunan chemical reagent work, lot number 961005.The ivens orchid, Shanghai chemical reagent purchasing and supply station.Analytical balance: the Shanghai second balance factory.721 type spectrophotometers: optical instrument factory, Shanghai.
2, test method and result
2, the clear micropill xylol of 1 gallbladder causes the influence of mice ear
The NIH white mice, ♂, 20----24g, 50, be divided into 5 groups at random, 10 every group, (1) matched group (distilled water), (2) XIAOYAN LIDAN PIAN group (19g crude drug/kg), (3)-(5) the clear micropill of function of gallbladder promoting is low, in, high dose group (6,12, the 24g crude drug/kg), press 20ml/kg body weight gastric infusion, once a day, continuous 7d, 30min causes inflammation for mice left side ear melted paraxylene 0.1ml after the last administration, after 120 minutes the disconnected cervical vertebra of mice is put to death, cutting ears along the basal part of the ear, is that the 9mm card punch is laid ear along the ear edge with diameter, and precision is weighed then, with two ear weight differences is inflammation swelling degree, the results are shown in Table 1.
The clear micropill xylol of table 1 function of gallbladder promoting cause mice auricle swelling influence (n=10, X=SD)
Group dosage swelling degree suppression ratio
(g/kg) (mg) (％)
Blank group 11.77 ± 2.13
XIAOYAN LIDAN PIAN 19 7.36 ± 2.89*** 37.5
The clear micropill 6 8.74 ± 3.38*** of function of gallbladder promoting △ 25.7
The clear micropill 12 6.88 ± 2.52*** of function of gallbladder promoting △ 41.5
The clear micropill 24 6.08 ± 2.96*** of function of gallbladder promoting △ 48.3
Compare * P＞0.05, * * * P＜0.01 with matched group; Compare △＞0.05 with the XIAOYAN LIDAN PIAN group.
The result shows: the clear micropill of function of gallbladder promoting can suppress the reaction of mice caused by dimethylbenzene xylene auricle edema, and wherein dosage is 12g/kg, and 24g/kg difference has the significance meaning.
2.2 the clear micropill of function of gallbladder promoting is to the influence of mouse peritoneal capillary permeability
White mice, 18---22g, is divided into 5 groups at random by 50, every group 10 (1) matched groups (distilled water), (2) (the 19g crude drug/kg), function of gallbladder promoting clear micropill in (3)-(5) is low for XIAOYAN LIDAN PIAN, in, high dose group (6,12,24g/kg), press 20ml/kg volume ig administration, continuous 7d, once a day, after the 7d administration, after every mouse peritoneal is injected 0.7% acetic acid 0.2ml, tail vein injection 1% Yi Wensilan 0.2ml immediately, put to death mice behind the 20min, cut open the belly, with normal saline 6ml flushing abdominal cavity, suction pipe sucking-off cleaning mixture, with normal saline 6ml flushing abdominal cavity, suction pipe sucking-off cleaning mixture is adjusted volume to 10ml with normal saline, add 0.1M NaOH0.1ml, the centrifugal 15min of 3000r/min gets supernatant in 721 spectrophotometers, under the wavelength 590nm, colorimetric determination optical density (OD), the comparable group differences, and calculate suppression ratio, the results are shown in Table 2.
The clear micropill of table 2 function of gallbladder promoting is to the influence (n=10 X=SD) of abdominal cavity capillary permeability
Group dosage optical density suppression ratio
(g/kg) (OD) (％)
Blank group 0.316 ± 0.093
XIAOYAN LIDAN PIAN 19 0.224 ± 0.082** 29.1
The clear micropill 6 0.256 ± 0.075* 19.0 of function of gallbladder promoting
△
The clear micropill 12 0.203 ± 0.073*** 35.8 of function of gallbladder promoting
△
The clear micropill 24 0.167 ± 0.052*** 47.2 of function of gallbladder promoting
△
Compare * P＜0.05, * * * P＜0.01 with matched group; Compare △ P＞0.05 with the XIAOYAN LIDAN PIAN group.
The result shows: the clear micropill of function of gallbladder promoting can suppress permeability capillaceous, has antiphlogistic effect.
2.3 the clear micropill of function of gallbladder promoting is to the excretory influence of rat bile
Rat, 60, ♂ is divided into 5 groups at random, and 12 every group, (1) matched group (distilled water), (2) trepibutone group (0.04/kg) behind the animal fasting 12h, with urethane (1g/kg) anesthesia, is sought common bile duct, and skewer is gone into round end scalp vein needle tubing, and the ligation circle is fixed.After treating the full conduit of bile, begin to store up record, in the 30min bile flow as administration before data.Distilled water is injected at 12 fat intestinal places under pylorus then, and the clear micropill concentration of function of gallbladder promoting is 30%, 60%, 120%.Trepibutone 0.4%, volume is 10ml/kg, collect and record administration 30min 60min, 90min, the bile flow of 120min, and get at every turn 0.1ml bile by literature method in 721 type spectrophotometer 540nm place colorimetrics, recording light density, and press the bilirubinic content of the red standard curve conversion of gallbladder bile, bile flow before (behind the medicine before the medicine)/medicine * 100% formula calculates bile flow increases percentage rate, the results are shown in Table 7.
Compare * * P＜0.05, * * * P＜0.01 with matched group; Compare △ P＜0.0, △ △ P＜0.05 with the trepibutone group.
The result shows: after the animal via duodenum gives the clear micropill of function of gallbladder promoting and trepibutone of various dose, behind medicine 30,60,90, the bile flow of 120min all is significantly increased, and compares with the blank group, and difference has the significance meaning, but bile flow descends gradually behind 60min, and clear micropill of results suggest function of gallbladder promoting and trepibutone all can promote the excretory effect of rat bile.
The clinical experiment data:
Clinically systematic observation 62 examples, 5 examples of fully recovering (8.1%), produce effects 32 examples (51.6%), effective 19 examples (30.6%), total effective rate reaches 90.3%, matched group (XIAOYAN LIDAN PIAN) has been observed 31 examples, 2 examples of fully recovering (6.5%), produce effects 10 examples (32.2%), effective 15 examples (48.4%), total effective rate reaches 87.1%, two group of total effective rate difference does not have significance meaning (P＞0.05), but between two groups of cure rate and the obvious effective rates significant difference (P＜0.01) is arranged, the clear micropill group of function of gallbladder promoting obviously is better than the XIAOYAN LIDAN PIAN group, alleviating stomachache, aspects such as abdominal distention, two groups have significant difference (P＜0.01), and sharp bright clear group is better than the XIAOYAN LIDAN PIAN group.Do not find tangible untoward reaction in the observation process.II phase comprehensive therapeutic effect shows: treatment group clinical recovery 7 examples (7.00%), and produce effects 56 examples (56.00%), effective 28 examples (28.00%), invalid 9 examples (9.00%), cure-remarkable-effectiveness rate 63.00%, total effective rate are 91.00%; Clinical recovery 5 examples (5.00%) of matched group DANNING PIAN, produce effects 44 examples (44.00%), effective 41 examples (41.00%), invalid 10 examples (10.00%), cure-remarkable-effectiveness rate is 59.00%, total effective rate is 90.00%.Relatively, there is statistical significance P＜0.05 between group, and treatment group curative effect is better than matched group.
The tcm syndrome curative effect: treatment group clinical recovery 14 examples (14.00%), produce effects 59 examples (59.00%), effective 22 examples (22.00%), invalid 5 examples (5.00%), cure-remarkable-effectiveness rate is 73.00%, total effective rate is 95.00%; Matched group clinical recovery 8 examples (8.00%), produce effects 51 examples (51.00%), effective 31 examples (31.00%), invalid 10 examples (10.00%), cure-remarkable-effectiveness rate is 59.00%, total effective rate is 90.00%.Relatively, there is statistical significance P＜0.05 between group, and treatment group curative effect is better than matched group.
III phase comprehensive therapeutic effect shows: treatment group clinical recovery 42 examples (13.95%), and produce effects 146 examples (48.50%), effective 95 examples (31.56%), invalid 18 examples (5.98%), cure-remarkable-effectiveness rate 62.46%, total effective rate are 94.01%; Clinical recovery 14 examples (11.57%) of matched group DANNING PIAN, produce effects 50 examples (41.32%), effective 42 examples (34.71%), invalid 15 examples (12.40%), cure-remarkable-effectiveness rate is 52.89%, total effective rate is 87.60%.Two groups relatively, and there is statistical significance P＜0.05, and treatment group curative effect is better than matched group.
The tcm syndrome curative effect: treatment group clinical recovery 55 examples (18.27%), produce effects 164 examples (54.49%), effective 65 examples (21.59%), invalid 17 examples (5.65%), cure-remarkable-effectiveness rate is 72.76%, total effective rate is 94.35%; Matched group clinical recovery 14 examples (11.57%), produce effects 61 examples (50.41%), effective 33 examples (27.27%), invalid 13 examples (10.74%), cure-remarkable-effectiveness rate is 62.98%, total effective rate is 89.26%.Two groups relatively, and there is statistical significance P＜0.05, and treatment group curative effect is better than matched group.
Further specify the present invention by the following examples.
The specific embodiment:
Embodiment 1
The preparation of pellet
Prescription
Herba Artemisiae Scopariae 950g Radix Scutellariae 855g Radix Bupleuri 855g Radix Curcumae 855g
Radix Notoginseng 190g Fructus Forsythiae 475g Fructus Amomi Rotundus 475g Rhizoma Corydalis 475g
Herba Menthae 475g
Seal after [method for making] Radix Notoginseng beats fine powder, use
60The sterilization of CO-radiation gamma is standby.Rhizoma Corydalis grinds the back with 80% ethanol extraction secondary, and 6 times of amounts were extracted 1.5 hours for the first time, adds 5 times of amounts the 2nd time to extract 1 hour, merges the secondary alcohol extract, and is standby behind the recovery ethanol.Six medicaments such as Herba Artemisiae Scopariae add 10 times of water gagings and soak into post-heating backflow 1 hour, regather the distillate of 6 times of amounts; Redistillation is collected volatile oil, and it is added beta-schardinger dextrin-polishing enclose, and dry back is standby.Mix above-mentioned medicinal residues, add 6 times of water gagings after adding Radix Scutellariae, boiled 2.0 hours, leach medicinal residues, add 5 times of water gagings again and boiled 1.5 hours, merging filtrate is incorporated the alcohol extract of Rhizoma Corydalis into when being evaporated to relative density and being 1.35～1.38 (60 ℃ of heat are surveyed), in 60 ℃ ,-0.08Mpa under vacuum drying, the gained extract powder is with the abundant mixing of Radix Notoginseng fine powder, Benexate Hydrochloride.Make the general ball of binding agent with 15% sucrose water, control ball footpath promptly gets the 1000g micropill after the drying about 2mm.[usage and consumption] is oral, and a 3.5g obeys three every day.
Embodiment 2
The preparation of tablet
Prescription
Herba Artemisiae Scopariae 475g Radix Scutellariae 427g Radix Bupleuri 427g Radix Curcumae 427g
Radix Notoginseng 95g Fructus Forsythiae 237g Fructus Amomi Rotundus 237g Rhizoma Corydalis 237g
Herba Menthae 237g
Seal after [method for making] Radix Notoginseng beats fine powder, use
60The sterilization of CO-radiation gamma is standby.Rhizoma Corydalis grinds the back with 80% ethanol extraction secondary, and 6 times of amounts were extracted 1.5 hours for the first time, adds 5 times of amounts the 2nd time to extract 1 hour, merges the secondary alcohol extract, and is standby behind the recovery ethanol.Six medicaments such as Herba Artemisiae Scopariae add 10 times of water gagings and soak into post-heating backflow 1 hour, regather the distillate of 6 times of amounts; Redistillation is collected volatile oil, and it is added beta-schardinger dextrin-polishing enclose, and dry back is standby.Mix above-mentioned medicinal residues, add 6 times of water gagings after adding Radix Scutellariae, boiled 2.0 hours, leach medicinal residues, add 5 times of water gagings again and boiled 1.5 hours, merging filtrate is incorporated the alcohol extract of Rhizoma Corydalis into when being evaporated to relative density and being 1.35～1.38 (60 ℃ of heat are surveyed), in 60 ℃ ,-0.08Mpa under vacuum drying, the gained extract powder is with the abundant mixing of Radix Notoginseng fine powder, Benexate Hydrochloride.Add starch, 95% ethanol system granule adds Pulvis Talci, magnesium stearate, and tabletting, coating get 1000 tablets of tablets.
Embodiment 3
The preparation of capsule
Prescription
Herba Artemisiae Scopariae 1900g Radix Scutellariae 1710g Radix Bupleuri 1710g Radix Curcumae 1710g
Radix Notoginseng 380g Fructus Forsythiae 950g Fructus Amomi Rotundus 950g Rhizoma Corydalis 950g
Herba Menthae 950g
Seal after [method for making] Radix Notoginseng beats fine powder, use
60The sterilization of CO-radiation gamma is standby.Rhizoma Corydalis grinds the back with 80% ethanol extraction secondary, and 6 times of amounts were extracted 1.5 hours for the first time, adds 5 times of amounts the 2nd time to extract 1 hour, merges the secondary alcohol extract, and is standby behind the recovery ethanol.Six medicaments such as Herba Artemisiae Scopariae add 10 times of water gagings and soak into post-heating backflow 1 hour, regather the distillate of 6 times of amounts; Redistillation is collected volatile oil, and it is added beta-schardinger dextrin-polishing enclose, and dry back is standby.Mix above-mentioned medicinal residues, add 6 times of water gagings after adding Radix Scutellariae, boiled 2.0 hours, leach medicinal residues, add 5 times of water gagings again and boiled 1.5 hours, merging filtrate is incorporated the alcohol extract of Rhizoma Corydalis into when being evaporated to relative density and being 1.35～1.38 (60 ℃ of heat are surveyed), in 60 ℃ ,-0.08Mpa under vacuum drying, the gained extract powder is with the abundant mixing of Radix Notoginseng fine powder, Benexate Hydrochloride.Add starch, 95% ethanol system granule adds magnesium stearate, the encapsulated 1000 seed lac wafers that get.
The clear micropill of table 7 function of gallbladder promoting to the influence of rat bile flow (n=12, X=SD)
Bile flow increases percentage rate (%) behind the group dosage body weight medicine prodrug
(g/kg) (g) (ml)
30min 60min 90min 120min
Matched group 293.4 ± 71.7 0.22 ± 0.08-1.27 ± 11.14-5.3 ± 8.35-6.91 ± 8.88-10.48 ± 16.14
Trepibutone 0.04 299.0 ± 71.0 0.20 ± 0.08 54.15 ± 30.00*** 44.75 ± 25.06 32.26 ± 27.62**, 14.32 ± 33.38**
Clear micropill 3.00 292.3 ± 87.0 0.19 ± 0.08 38.88 ± 24.12***, 20.12 ± 17.62***, the 13.60 ± 20.53*** of function of gallbladder promoting 5.64 ± 14.86**
△ △△ △ △
Clear micropill 6.00 291.8 ± 74.2 0.17 ± 0.08 43.51 ± 27.50***, 43.80 ± 51.36***, the 19.02 ± 20.24*** of function of gallbladder promoting 1.02 ± 3.67**
△ △ △ △
Clear micropill 12.00 295.9 ± 81.6 0.21 ± 0.08 37.64 ± 19.41***, 25.27 ± 26.61***, the 17.66 ± 23.78*** of function of gallbladder promoting 2.33 ± 10.25**
△ △ △ △
Claims (7)
1, a kind of Chinese medicine preparation for the treatment of cholecystitis is characterized in that, it is made by the Chinese medicine of following component,
Herba Artemisiae Scopariae 475-1900 part Radix Scutellariae 427-1710 part Radix Bupleuri 427-1710 part Radix Curcumae 427-1710 part
Radix Notoginseng 95-380 part Fructus Forsythiae 237-950 part Fructus Amomi Rotundus 237-950 part Rhizoma Corydalis 237-950 part
Herba Menthae 237-950 part.
According to the Chinese medicine preparation of claim 1, it is characterized in that 2, it is made by the Chinese medicine of following component,
Herba Artemisiae Scopariae 712-1266 part Radix Scutellariae 641-1140 part Radix Bupleuri 641-1140 part Radix Curcumae 641-1140 part
Radix Notoginseng 142-253 part Fructus Forsythiae 356-633 part Fructus Amomi Rotundus 356-633 part Rhizoma Corydalis 356-633 part
Herba Menthae 356-633 part.
According to the Chinese medicine preparation of claim 1, it is characterized in that 3, it is made by the Chinese medicine of following component,
855 parts of 855 portions of Radix Curcumaes of 855 parts of Radix Bupleuri of 950 parts of Radix Scutellariaes of Herba Artemisiae Scopariae
475 parts of 475 parts of Rhizoma Corydalis of 475 parts of Fructus Amomi Rotunduss of 190 parts of Fructus Forsythiaes of Radix Notoginseng
475 parts of Herba Menthaes.
4, according to any one Chinese medicine preparation of claim 1-3, it is characterized in that described preparation is a pellet, tablet, capsule, oral liquid, buccal tablet, granule, electuary, pill, powder, suspensoid, powder, solution, drop or drop pill.
According to the Chinese medicine preparation of claim 4, it is characterized in that 5, described preparation is a pellet.
6. the application of the Chinese medicine preparation of claim 1 in the medicine of preparation treatment cholecystitis.
According to the preparation method of the Chinese medicine preparation of claim 1, it is characterized in that 7, through following steps, Radix Notoginseng seals after beating fine powder, use
60The sterilization of CO-radiation gamma is standby.Rhizoma Corydalis grinds the back with 80% ethanol extraction secondary, and 6 times of amounts were extracted 1.5 hours for the first time, adds 5 times of amounts the 2nd time to extract 1 hour, merges the secondary alcohol extract, and is standby behind the recovery ethanol.Six medicaments such as Herba Artemisiae Scopariae add 10 times of water gagings and soak into post-heating backflow 1 hour, regather the distillate of 6 times of amounts; Redistillation is collected volatile oil, and it is added beta-schardinger dextrin-polishing enclose, and dry back is standby.Mix above-mentioned medicinal residues, add 6 times of water gagings after adding Radix Scutellariae, boiled 2.0 hours, leach medicinal residues, adding 5 times of water gagings again boiled 1.5 hours, merging filtrate is incorporated the alcohol extract of Rhizoma Corydalis into when being evaporated to relative density and being 1.35～1.38 (60 ℃ of heat are surveyed), in 60 ℃ ,-0.08Mpa under vacuum drying, the gained extract powder, Radix Notoginseng fine powder, Benexate Hydrochloride are made the pharmaceutical dosage form that is fit to take together as pharmaceutically active substance with this pharmaceutically active substance with the galenic pharmacy routine techniques.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410086352 CN1634407A (en) | 2004-10-26 | 2004-10-26 | Chinese traditional medicine preparation for treating cholecystitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410086352 CN1634407A (en) | 2004-10-26 | 2004-10-26 | Chinese traditional medicine preparation for treating cholecystitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1634407A true CN1634407A (en) | 2005-07-06 |
Family
ID=34847424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410086352 Pending CN1634407A (en) | 2004-10-26 | 2004-10-26 | Chinese traditional medicine preparation for treating cholecystitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1634407A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101045116B (en) * | 2007-04-18 | 2010-05-26 | 孙晓波 | Traditional Chinese medicine for treating cholecystitis |
| CN102359997A (en) * | 2011-06-22 | 2012-02-22 | 吉林省辉南长龙生化药业股份有限公司 | Lidanqing Wan and discriminating method therefor |
| CN103055060A (en) * | 2012-12-04 | 2013-04-24 | 青岛绿曼生物工程有限公司 | Compound propolis composition for treating cholecystitis of cattle and preparation method of compound propolis composition |
| CN105497409A (en) * | 2014-10-28 | 2016-04-20 | 刘波 | Traditional Chinese medicine for treating cholecystitis |
-
2004
- 2004-10-26 CN CN 200410086352 patent/CN1634407A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101045116B (en) * | 2007-04-18 | 2010-05-26 | 孙晓波 | Traditional Chinese medicine for treating cholecystitis |
| CN102359997A (en) * | 2011-06-22 | 2012-02-22 | 吉林省辉南长龙生化药业股份有限公司 | Lidanqing Wan and discriminating method therefor |
| CN102359997B (en) * | 2011-06-22 | 2014-04-09 | 吉林省辉南长龙生化药业股份有限公司 | Discriminating method for lidanqing Wan |
| CN103055060A (en) * | 2012-12-04 | 2013-04-24 | 青岛绿曼生物工程有限公司 | Compound propolis composition for treating cholecystitis of cattle and preparation method of compound propolis composition |
| CN103055060B (en) * | 2012-12-04 | 2014-12-03 | 青岛绿曼生物工程有限公司 | Compound propolis composition for treating cholecystitis of cattle and preparation method of compound propolis composition |
| CN105497409A (en) * | 2014-10-28 | 2016-04-20 | 刘波 | Traditional Chinese medicine for treating cholecystitis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1943610A (en) | Chinese medicine preparation for traumatic injury and blood stasis and swelling pain | |
| CN1823992A (en) | Ginseny spleen invigorating preparation and its new preparation method | |
| CN1785371A (en) | Chinese medicinal preparation for abating child fever and its preparation method | |
| CN1824035A (en) | Swim bladder kidney nourishing preparation and its preparation method | |
| CN1299702C (en) | Preparation of medicine preparation of orthopedics department and its use | |
| CN1679706A (en) | Medicinal preparation containing notoginseng and rhodiola root for cardio-cerebral blood vessel diseases and its preparing method | |
| CN1679697A (en) | Chinese medicine preparation for treating cardio vascular disease and containing notoginseng, pericarpium trichosanthis and leech, for treating cardio-cerebral blood vessel diseases and its preparing | |
| CN1232279C (en) | Antilipemic Chinese medicine | |
| CN1686469A (en) | Medicament for treating coronary heart disease and its preparation method | |
| CN102716283B (en) | Hypolipidemic traditional Chinese medicine | |
| CN1634407A (en) | Chinese traditional medicine preparation for treating cholecystitis | |
| CN1853688A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof | |
| CN1943734A (en) | A Chinese traditional medicine for clearing away heat and toxic material | |
| CN1853689A (en) | Chinese medicinal preparation for treating heart cerebrovascular disease and making method thereof | |
| CN1742871A (en) | Gamboge bone-tonifying preparation and new preparation method thereof | |
| CN100342888C (en) | Chinese medicine preparation for treating prostatic hyperplasia | |
| CN1939480A (en) | Chinese-medicinal compound preparation for treating injury | |
| CN1824100A (en) | Medicinal preparation for treating cough and panting and its preparation method | |
| CN1857684A (en) | Compound Chinese medicine preparation for removing toxic matter, dispersing blood clots and strengthing body's resistance and its preparaing process | |
| CN1191849C (en) | Chinese medicine for treating breast disease | |
| CN1824270A (en) | Middle-jiao regulating medicinal preparation and its new preparation method | |
| CN1775258A (en) | Womb-warming pregnancy-aiding preparation and new preparing method | |
| CN1192793C (en) | Heart failure resisting Chinese medicine | |
| CN1748741A (en) | Little leaf deervetch herb acne removing preparation and new preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |